4D pharma: A clinical stage innovator and pioneer of Live Biotherapeutics, 8 June 2020

4D's CEO Duncan Peyton discusses the advantages of 4D's unique approach to Live Biotherapeutics with Proactive Investors

4D pharma PLC about to start dosing patients in its Phase II trial for COVID-19, 29 May 2020

Watch Proactive Investor's Andrew Scott interview 4D's CEO, Duncan Peyton, discussing the company's recent progress in the clinic in oncology and IBS, its Phase II clinical trial in COVID-19, and more

4D pharma receives MHRA approval for Phase II COVID-19 trial

European Pharmaceutical Review, 22 April 2020

BioCentury, 21 April 2020

Pharma Business International, 20 April 2020

Pharmafield, 20 April 2020

Contract Pharma, 20 April 2020

BioSpace: 4D pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate, 17 March 2020

4D presents additional data from its ongoing Phase I/II trial of LBP MRx0518 in combination with Keytruda® at Chardan's virtual 2nd Annual Microbiome Medicines Summit